FDA issued a draft guidance document for developing plans to enroll more participants in clinical trials from underrepresented racial and ethnic populations. The draft guidance advises sponsors of medical products to develop and submit a race and ethnicity diversity plan based on a framework outlined in the guidance to the agency early in clinical development.

COVID-19 has intensified the mental health pandemic, said Julie A. Dopheide, PharmD, BCPP, FASHP. What’s worse is that access to mental health care continues to be a challenge for individuals.

DEA administrator Anne Milgram announced the agency’s continued support for expanding access to medication-assisted treatment (MAT) to help individuals with substance use disorder.